XB773
/ Exelixis
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 11, 2026
Anticipated R&D Milestones:…Two Potential IND Applications in 2026
(Businesswire)
- "Exelixis anticipates advancing two programs into clinical development this year: (i) XL557 is an orally bioavailable small molecule Somatostatin Receptor 2 agonist. Somatostatin analogs are widely used in the first- and second-line NET treatment settings....; (ii) XB773 is an antibody-drug conjugate (ADC) consisting of an exatecan payload conjugated to a monoclonal antibody targeting DLL3, a transmembrane protein that is expressed in neuroendocrine carcinomas such as small cell lung cancer and neuroendocrine prostate cancer."
IND • Genitourinary Neuroendocrine Carcinoma • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Prostate Cancer • Small Cell Lung Cancer
January 09, 2022
Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022
(Businesswire)
- "Potential new development candidates:...With respect to biotherapeutics, these include XB010, the first custom ADC generated through the company’s collaboration network, which was designated a development candidate in late 2021 and will enter preclinical development shortly....Additional ADCs advancing through discovery target a range of tumor antigens including AMHR2, ROR1/2, TF and DLL3 and utilize a variety of conjugation technologies and payloads. In addition, Exelixis is advancing two bispecific programs through its Invenra collaboration that combine a PD-L1 targeting arm with either a CD47 targeting arm to block a macrophage checkpoint, or an NKG2A targeting arm to promote NK cell activation in the tumor microenvironment."
Pipeline update • Oncology
1 to 2
Of
2
Go to page
1